Agios Unveils Latest Pyrukynd Mitapivat Findings: Promising Long-Term Safety and Hemoglobin Improvement in Non-Transfusion Dependent Patients
Agios Pharmaceuticals Presents Updated PYRUKYND® Data Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Agios Pharmaceuticals, Inc. is currently conducting Phase 3 ENERGIZE and ENERGIZE-T studies to evaluate the effectiveness of PYRUKYND® in adults with non-transfusion-dependent and transfusion-dependent α- or β-Thalassemia, respectively. This innovative drug has shown promise in improving outcomes for patients with these…